Sakari Hietanen

Also affiliated with Nordic Society of Gynecologic Oncology

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 5 papers. Top paper: “Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study”.

Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.04.012

N/A

1.3DataRank · unranked

36 citations

José Alejandro Pérez Fidalgo, Bradley J. Monk, Ignacio Tusquets, Colleen McCormick, José Fuentes +20 more

Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer

Gynecologic Oncology(2023)10.1016/j.ygyno.2023.06.018

N/A

0.908DataRank · unranked

28 citations

Michael A. Bookman, Jalid Sehouli, Austin Miller, Richard T. Penson, Çağatay Taşkıran +20 more

Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial

JCO Precision Oncology(2023)10.1200/po.22.00258

N/A

0.612DataRank · unranked

58 citations

Jessica Brown, Alan Barnicle, Jonathan Wessen, Pierre Lao-Sirieix, Steven W. Criscione +16 more

Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial

Gynecologic Oncology(2024)10.1016/j.ygyno.2024.03.009

N/A

0.473DataRank · unranked

7 citations

Bhavana Pothuri, Ana Oaknin, Whitney S. Graybill, Ana Beatriz Sánchez, Colleen McCormick +15 more

Multi-modal characterization of transcriptional programs that drive metastatic cascades to solid sites and ascites in ovarian cancer

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.08.26.672372

N/A

0DataRank · unranked

1 citations

Essi Kahelin, Giovanni Marchi, Oskari Lehtonen, Shams Salloum, Kari Lavikka +10 more